These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

829 related items for PubMed ID: 30227157

  • 1. Glucagon-like peptide-1 receptor action in the vasculature.
    Almutairi M, Al Batran R, Ussher JR.
    Peptides; 2019 Jan; 111():26-32. PubMed ID: 30227157
    [Abstract] [Full Text] [Related]

  • 2. Glucagon-like peptide-1 receptor mediated control of cardiac energy metabolism.
    Al Batran R, Almutairi M, Ussher JR.
    Peptides; 2018 Feb; 100():94-100. PubMed ID: 29412838
    [Abstract] [Full Text] [Related]

  • 3. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA, Meier JJ, Cavender MA, Abd El Aziz M, Drucker DJ.
    Circulation; 2017 Aug 29; 136(9):849-870. PubMed ID: 28847797
    [Abstract] [Full Text] [Related]

  • 4. Cardiovascular benefits of GLP-1 agonists in type 2 diabetes: a comparative review.
    Boyle JG, Livingstone R, Petrie JR.
    Clin Sci (Lond); 2018 Aug 16; 132(15):1699-1709. PubMed ID: 30115742
    [Abstract] [Full Text] [Related]

  • 5. GLP-1R as a Target for the Treatment of Diabetic Retinopathy: Friend or Foe?
    Simó R, Hernández C.
    Diabetes; 2017 Jun 16; 66(6):1453-1460. PubMed ID: 28533296
    [Abstract] [Full Text] [Related]

  • 6. Incretin-mediated control of cardiac energy metabolism.
    Chan JSF, Shafaati T, Ussher JR.
    J Endocrinol; 2024 Oct 01; 263(1):. PubMed ID: 39013412
    [Abstract] [Full Text] [Related]

  • 7. Glucagon-like Peptide-1 receptor Tie2+ cells are essential for the cardioprotective actions of liraglutide in mice with experimental myocardial infarction.
    McLean BA, Wong CK, Kabir MG, Drucker DJ.
    Mol Metab; 2022 Dec 01; 66():101641. PubMed ID: 36396031
    [Abstract] [Full Text] [Related]

  • 8. Sgemaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)?
    Doggrell SA.
    Expert Opin Drug Metab Toxicol; 2018 Mar 01; 14(3):371-377. PubMed ID: 29439603
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Glucagon-like peptide 1-related peptides increase nitric oxide effects to reduce platelet activation.
    Barale C, Buracco S, Cavalot F, Frascaroli C, Guerrasio A, Russo I.
    Thromb Haemost; 2017 Jun 02; 117(6):1115-1128. PubMed ID: 28405672
    [Abstract] [Full Text] [Related]

  • 12. How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.
    Lee MMY, Petrie MC, McMurray JJV, Sattar N.
    Arterioscler Thromb Vasc Biol; 2020 Mar 02; 40(3):506-522. PubMed ID: 31996025
    [Abstract] [Full Text] [Related]

  • 13. Immunohistochemical assessment of glucagon-like peptide 1 receptor (GLP-1R) expression in the pancreas of patients with type 2 diabetes.
    Kirk RK, Pyke C, von Herrath MG, Hasselby JP, Pedersen L, Mortensen PG, Knudsen LB, Coppieters K.
    Diabetes Obes Metab; 2017 May 02; 19(5):705-712. PubMed ID: 28094469
    [Abstract] [Full Text] [Related]

  • 14. Impact of GLP-1 and GLP-1 receptor agonists on cardiovascular risk factors in type 2 diabetes.
    Verge D, López X.
    Curr Diabetes Rev; 2010 Jul 02; 6(4):191-200. PubMed ID: 20380625
    [Abstract] [Full Text] [Related]

  • 15. Assessment of Cardiovascular Risk With Glucagon-Like Peptide 1 Receptor Agonists in Patients With Type 2 Diabetes Using an Alternative Measure to the Hazard Ratio.
    Kaneko M, Narukawa M.
    Ann Pharmacother; 2018 Jul 02; 52(7):632-638. PubMed ID: 29424239
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. GLP-1 receptor agonists and cardiovascular outcome trials: An update.
    Andrikou E, Tsioufis C, Andrikou I, Leontsinis I, Tousoulis D, Papanas N.
    Hellenic J Cardiol; 2019 Jul 02; 60(6):347-351. PubMed ID: 30528435
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. GLP-1 and insulin regulation of skeletal and cardiac muscle microvascular perfusion in type 2 diabetes.
    Love KM, Liu J, Regensteiner JG, Reusch JEB, Liu Z.
    J Diabetes; 2020 Jul 02; 12(7):488-498. PubMed ID: 32274893
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.